NIPER Mohali career outcomes reflect the institute’s research orientation. The 2025 placement cycle recorded a highest CTC of INR 15 LPA (Pfizer) and an average CTC of INR 6 to 8 LPA for PG graduates. Of 268 eligible students, 213 were placed, reflecting a placement rate of 79%. Over 40 companies participated, with pharma contributing 80% and biotech 15% of the total offers.
| Programme | 2025 Highest CTC | 2025 Average CTC | Key Sectors |
|---|---|---|---|
| M.Pharm (all streams) | INR 15 LPA (Pfizer) | INR 6 to 8 LPA | R&D, Regulatory |
| MS (Pharm) | INR 12 to 15 LPA | INR 6 to 7 LPA | Biotech, Pharmacoinformatics |
| MBA (Pharma Management) | INR 10 LPA (Novartis) | INR 7 to 9 LPA | Commercial, Regulatory |
Top recruiters from the 2025 cycle included Pfizer, Mylan, Zydus Cadila, Syngene, Himalaya, and Novartis. R&D roles accounted for 75% of all placements, with regulatory affairs taking a further 20%. A significant share of NIPER graduates also pursue Ph.D or post-doctoral research in India and abroad, particularly in the United States, Europe, and Canada.




